Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biotechnology leader focused on central nervous system therapeutics and advanced drug delivery systems. This page provides investors and industry observers with timely updates on clinical trial progress, regulatory developments, and strategic initiatives critical to evaluating the company's position in the CNS treatment market.
Access consolidated information on NTHI's proprietary NEO platform advancements, intellectual property milestones, and collaborative research partnerships. The resource covers essential updates including FDA designations, trial phase results, and executive commentary without speculative analysis.
Key content types include earnings communications, clinical trial status reports, patent filings, and leadership updates. All materials maintain compliance with financial disclosure regulations while emphasizing technological developments in blood-brain barrier penetration techniques.
Bookmark this page for streamlined tracking of NTHI's progress in addressing complex neurological conditions through its innovative therapeutic pipeline. Regular updates ensure stakeholders remain informed about developments that may influence long-term research trajectories and market positioning.
NeOnc Technologies (NASDAQ: NTHI), a multi-Phase 2 clinical-stage biotech company, has completed all contingencies for a $50 million strategic partnership with Quazar Investment following the incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM).
The partnership involves Quazar Investment taking majority control of NuroMENA Holdings, which will serve as NeOnc's UAE-based subsidiary overseeing regional clinical operations in the Middle East and North Africa. The collaboration aims to accelerate the development of NeOnc's CNS therapeutic pipeline, including the NEO212 and NEO100 clinical programs for brain cancer treatment.
Quazar Investment, managing over $3.3 billion in assets, will provide strategic support to expand NeOnc's CNS platform across the MENA region, with joint governance oversight between both companies.
NeOnc Technologies (NASDAQ: NTHI) has secured $2.5 million in NIH STTR grants to advance its proprietary compound NEO212. The funding includes a $400,000 Phase 1 grant for acute myelogenous leukemia (AML) studies and a $2.1 million Phase 2 grant for newly diagnosed gliomas research.
The company is currently completing Phase 1 clinical trials for NEO212, with these non-dilutive funds supporting its expansion into new indications. The grants are structured as collaborative developments between NeOnc (40% funding) and USC-based research collaborators (60% funding), led by Dr. Thomas Chen as Principal Investigator.
NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on brain and central nervous system cancer treatments, was featured on Yahoo Finance's Trader Talk podcast. The episode highlights the company's recent achievements, including its successful IPO, a $50 million partnership in the Middle East, and inclusion in the Russell Microcap Index.
The podcast discussion with Executive Chairman Amir Heshmatpour covers NeOnc's innovative intranasal drug delivery approach for brain cancer, its strategic partnership with USC's medical school, and the expansion of global clinical trials. The conversation also explores the potential impact of AI and quantum computing in biotechnology.
NeOnc Technologies (NASDAQ: NTHI), a Phase 2 clinical-stage biotech company, has announced a definitive agreement to acquire an advanced IP portfolio from Dr. Ishwar K. Puri for $3.5 million, consisting of $500,000 in cash and $3 million in common stock at $25 per share.
The acquisition includes U.S. Patent No. 11,788,057 B2 featuring 3D bioprinting, AI, and quantum modeling technologies for brain-targeted therapy development. The IP will integrate with NeOnc's platform and Middle East partnership with Quazar Investment Group. Additionally, Dr. Puri, currently Senior Vice President of Research and Innovation at USC and ranked among the top 0.4% of global scholars, joins NeOnc's Board of Directors.
NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on brain and CNS cancer treatments, has secured a $50 million strategic partnership with Quazar Investment. The agreement includes a $35 million equity investment at $25 per share for 1.4 million shares, with the remaining $15 million allocated for Phase 2B clinical trials and infrastructure development in the UAE and MENA region.
The partnership involves the formation of NuroMENA and NuroCure entities in Abu Dhabi, pending UAE government approval. The transaction must be completed within 120 days and includes specific conditions for the legal establishment of these entities.
NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on developing treatments for brain and central nervous system cancers, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
Interested investors can arrange one-on-one meetings with the company's management team through their BTIG representative or by contacting James@HaydenIR.com.
NeOnc Technologies Holdings (NTHI) announced that Executive Chairman & President Amir Heshmatpour will participate in a live interview with Kenny Polcari on YouTube.com/@Floorstocks on July 24, 2025, at 11:00 a.m. ET.
The interview follows NeOnc's recent execution of a Sub-License Agreement with NuroCure, its Abu Dhabi subsidiary, marking progress toward a $50 million strategic partnership with Quazar Investment covering the UAE, GCC, and MENA regions. The company was also recently included in the Russell Microcap Index.
NeOnc is advancing two key therapeutics, NEO100™ and NEO212™, currently in Phase II clinical trials with FDA Fast-Track and IND status. These drug candidates, developed through the company's NEO™ platform, target brain and central nervous system cancers with patent protection until 2038.
NeOnc Technologies (NTHI), a clinical-stage biotech company focused on brain and central nervous system cancer treatments, announces a live interview featuring Executive Chairman Amir Heshmatpour with Kenny Polcari on YouTube.com/@Floorstocks on July 23, 2025, at 11:00 a.m. ET.
The interview follows two significant developments: the execution of a Sub-License Agreement with NuroCure for the UAE, GCC, and MENA regions as part of a $50 million strategic partnership with Quazar Investment, and the company's inclusion in the Russell Microcap Index. NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II clinical trials with FDA Fast-Track status, targeting malignant gliomas with patent protection until 2038.
NeOnc Technologies (NTHI) has executed a crucial Sub-License Agreement with its Abu Dhabi subsidiary NuroCure, marking significant progress toward closing a $50 million strategic partnership with Quazar Investment. The agreement, covering NEO100 and NEO212 in the UAE and MENA region, represents the second of five required conditions for the transaction.
The partnership, priced at $25 per share, allocates 70% for NeOnc common stock acquisition and 30% for MENA region clinical trials and infrastructure. The company must complete three remaining conditions within 120 days, including forming NuroMENA and NuroCure in Abu Dhabi, finalizing offering documents, and approving a two-year business plan.
NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials with FDA Fast-Track status, targeting brain and central nervous system cancers.
NeOnc Technologies (NASDAQ: NTHI) has secured board approval for a strategic $50 million partnership with Quazar Investment. The board unanimously approved the company's participation in the equity investment and MENA region expansion on June 30, 2025, marking the first of five required milestones.
The proposed structure includes a $25 per share pricing, with 70% of proceeds allocated to NeOnc common stock acquisition and 30% dedicated to clinical trials and infrastructure development in the UAE and MENA region. The company must complete remaining conditions within 120 days, including establishing NuroMENA and NuroCure in Abu Dhabi, executing licensing agreements for NEO100 and NEO212, and finalizing offering documents and business plans.
FAQ
What is the current stock price of NeOnc Technologies Holdings (NTHI)?
What is the market cap of NeOnc Technologies Holdings (NTHI)?
